Symbol
| SLC2A8
| contributors: mct - updated : 18-03-2020
|
HGNC name
| solute carrier family 2, (facilitated glucose transporter) member 8
|
HGNC id
| 13812
|
Other morbid association(s)
|
Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
---|
constitutional
|  
|  
| --over
|  
|
in human IUGR-affected pregnancies on the maternal aspect of the placenta (extravillous trophoblastic (EVT) cytoplasm) compared to control | |
Variant & Polymorphism
|
| |
Candidate gene
Marker
Therapy target
|
System | Type | Disorder | Pubmed |
cancer | | | |
therapeutic strategy entailing selective SLC2A4, SLC2A11, SLC2A8 inhibition to specifically target aberrant glucose metabolism in cancer | diabete | type 2 | | |
is a promising target in the prevention of diet-induced obesity, and type 2 diabetes mellitus in males | diabete | metabolic syndrom | | |
is a promising target in the prevention of diet-induced obesity, metabolic syndrome in males |
| | | |
| behavioral alterations of Slc2a8 -/- mice are due to dysfunctions in neuronal processes presumably as a consequence of defects in the glucose metabolism | |
Glut8KO mice exhibited significantly greater jejunal fructose uptake at baseline and after high-fructose diet (HFrD) feeding vs. wild-type mice |